Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | hypothetical protein | 0.0036 | 0.0317 | 0.2612 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.0053 | 0.0799 | 0.6593 |
Toxoplasma gondii | enoyl-acyl carrier reductase ENR | 0.037 | 1 | 1 |
Trypanosoma brucei | oxidoreductase-like protein | 0.0025 | 0 | 0.5 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.0053 | 0.0799 | 0.6593 |
Brugia malayi | TAR-binding protein | 0.0067 | 0.1213 | 1 |
Leishmania major | dehydrogenase/oxidoreductase-like protein | 0.0025 | 0 | 0.5 |
Leishmania major | dehydrogenase/oxidoreductase-like protein | 0.0025 | 0 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0038 | 0.0375 | 1 |
Leishmania major | pteridine reductase 1 | 0.0025 | 0 | 0.5 |
Plasmodium falciparum | enoyl-acyl carrier reductase | 0.037 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0038 | 0.0375 | 0.3091 |
Trypanosoma cruzi | beta-ketoacyl-ACP reductase | 0.0025 | 0 | 0.5 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.0053 | 0.0799 | 0.6593 |
Brugia malayi | RNA binding protein | 0.0067 | 0.1213 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0036 | 0.0317 | 0.2612 |
Schistosoma mansoni | tar DNA-binding protein | 0.0067 | 0.1213 | 1 |
Trypanosoma cruzi | oxidoreductase-like protein, putative | 0.0025 | 0 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | enoyl-ACP reductase | 0.037 | 1 | 1 |
Leishmania major | oxidoreductase-like protein | 0.0025 | 0 | 0.5 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0036 | 0.0317 | 0.2612 |
Loa Loa (eye worm) | RNA binding protein | 0.0067 | 0.1213 | 1 |
Onchocerca volvulus | 0.0025 | 0 | 0.5 | |
Echinococcus granulosus | Basic leucine zipper bZIP transcription | 0.0038 | 0.0375 | 0.3091 |
Schistosoma mansoni | tar DNA-binding protein | 0.0067 | 0.1213 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0067 | 0.1213 | 1 |
Onchocerca volvulus | 0.0025 | 0 | 0.5 | |
Echinococcus multilocularis | tar DNA binding protein | 0.0067 | 0.1213 | 1 |
Mycobacterium leprae | NADH-DEPENDENT ENOYL-[ACYL-CARRIER-PROTEIN] REDUCTASE INHA (NADH-DEPENDENT ENOYL-ACP REDUCTASE) | 0.037 | 1 | 1 |
Mycobacterium tuberculosis | NADH-dependent enoyl-[acyl-carrier-protein] reductase InhA (NADH-dependent enoyl-ACP reductase) | 0.037 | 1 | 1 |
Trichomonas vaginalis | hypothetical protein | 0.037 | 1 | 0.5 |
Plasmodium vivax | enoyl-acyl carrier protein reductase | 0.037 | 1 | 1 |
Brugia malayi | hypothetical protein | 0.0038 | 0.0375 | 0.3091 |
Trypanosoma cruzi | beta-ketoacyl-ACP reductase | 0.0025 | 0 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0038 | 0.0375 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0067 | 0.1213 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0038 | 0.0375 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0067 | 0.1213 | 1 |
Schistosoma mansoni | transcription factor LCR-F1 | 0.0038 | 0.0375 | 0.3091 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0067 | 0.1213 | 1 |
Mycobacterium ulcerans | enoyl-(acyl carrier protein) reductase | 0.037 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0053 | 0.0799 | 0.6593 |
Echinococcus granulosus | tar DNA binding protein | 0.0067 | 0.1213 | 1 |
Leishmania major | 3-oxoacyl-ACP reductase, putative | 0.0025 | 0 | 0.5 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0067 | 0.1213 | 1 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription | 0.0038 | 0.0375 | 0.3091 |
Entamoeba histolytica | hypothetical protein | 0.0038 | 0.0375 | 1 |
Trypanosoma brucei | beta-ketoacyl-ACP reductase | 0.0025 | 0 | 0.5 |
Loa Loa (eye worm) | TAR-binding protein | 0.0067 | 0.1213 | 1 |
Trypanosoma brucei | pteridine reductase 1 | 0.0025 | 0 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.